Overview
GILD market data
Price History
GILD price chart
Valuation & Profitability
- P/E (TTM)
- 19.42 Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- $6.78 Diluted earnings per share over the trailing twelve months.
- Beta
- 0.33 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- 2.4% Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- -10.6% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $108.46 – $157.29 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $165.2B · P/B 6.71 · P/S 5.42.
Company News
KLA, Snowflake, Airbnb And A Health Care Stock On CNBC’s ‘Final Trades’Benzinga · Aug 12, 2026, 12:44 PM
MacroGenics Announces Gilead Sciences Exercises Option For Exclusive License To Preclinical Bispecific Program Under 2022 Collaboration, Triggering $10M PaymentBenzinga · Aug 11, 2026, 8:22 PM
CNBC Halftime Report Final Trades: Airbnb, Gilead Sciences, KLA, SnowflakeBenzinga · Aug 11, 2026, 5:01 PM
Top C-suite Executives Recognized at the 2026 National ORBIE AwardsGlobenewswire Inc · Aug 7, 2026, 3:15 PM
Kathy Hochul Slams Trump Over Medicare Cut, Says 1.3 Million New Yorkers Will Pay More for Prescriptions: 'A New Assault on Seniors...'Benzinga · Aug 6, 2026, 7:41 AM
State Street XLV vs VanEck BBH: Which Healthcare ETF Is the Better Buy in 2026?The Motley Fool · Aug 5, 2026, 8:15 PM
RBC Capital Maintains Sector Perform on Gilead Sciences, Raises Price Target to $123Benzinga · Aug 5, 2026, 4:16 PM
Cantor Fitzgerald Reiterates Overweight on Gilead Sciences, Maintains $155 Price TargetBenzinga · Aug 5, 2026, 12:52 PM
Needham Reiterates Buy on Gilead Sciences, Maintains $170 Price TargetBenzinga · Aug 5, 2026, 10:02 AM
Gilead Sciences Exec Says Raising Full Year HIV Growth Expectations To 9%-10% YoY From Prior Guidance Of 8% Growth; Launch Preparations Fully Underway For Anito-Cel Cell Therapy, With Five Months To Go Until FDA PDUFA Date; Do Not Currently Anticipate Pursuing Additional Sizable M&A Transactions This YearBenzinga · Aug 4, 2026, 9:17 PM